New players in the pathogenesis of focal segmental glomerulosclerosis

Nephrology Dialysis Transplantation

Volumn 27, Issue 9, 2012, Pages 3406-3412

  Schell, Christoph ^a,b   Huber, Tobias B ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Arhgap24; CD2AP; FSGS; podocyte; suPAR

Indexed keywords

CATHEPSIN L; CD2 ASSOCIATED PROTEIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MYOSIN I; PROTEIN ARHGAP24; PROTEIN MYO1E; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ARHGAP24 GENE; CELL FUNCTION; CELL MOTILITY; CYTOSKELETON; FOCAL GLOMERULOSCLEROSIS; GENE; GENE FUNCTION; HUMAN; INTRACELLULAR SIGNALING; LOSS OF FUNCTION MUTATION; MUTATIONAL ANALYSIS; MYO1E GENE; NONHUMAN; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; STOMACH PARIETAL CELL;

ANIMALS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; RISK FACTORS;

EID: 84865740722     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs273     Document Type: Review

References (58)

1. Meyrier A. Mechanisms of disease: focal segmental glomerulosclerosis. Nat Clin Pract Nephrol 2005; 1: 44-54.
2. Gbadegesin R et al. Pathogenesis and therapy of focal segmental glomerulosclerosis: an update. Pediatr Nephrol 2011; 26: 1001-1015.
3. D'Agati VD. The spectrum of focal segmental glomerulosclerosis: new insights. Curr Opin Nephrol Hypertens 2008; 17: 271-81.
4. D'Agati VD et al. Focal segmental glomerulosclerosis. N Engl J Med 2011; 365: 2398-2411.
5. D'Agati VD. Pathophysiology of focal segmental glomerulosclerosis: new developments. Curr Opin Nephrol Hypertens 2012; 21: 243-250.
6. D'Agati VD et al. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 2004; 43: 368-382.
7. Schonenberger E et al. The podocyte as a direct target of immunosuppressive agents. Nephrol Dial Transplant 2011; 26: 18-24.
8. Fornoni A et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011; 3: 85ra46.
9. Faul C et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008; 14: 931-938.
10. Kestila M et al. Positionally cloned gene for a novel glomerular protein-nephrin-is mutated in congenital nephrotic syndrome. Mol Cell 1998; 1: 575-582.
11. Santin S et al. Nephrin mutations cause childhood-and adult-onset focal segmental glomerulosclerosis. Kidney Int 2009; 76: 1268-1276.
12. Koziell A et al. Genotype/phenotype correlations of NPHS1 and NPHS2 mutations in nephrotic syndrome advocate a functional inter-relationship in glomerular filtration. Hum Mol Genet 2002; 11: 379-388.
13. Boute N et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000; 24: 349-354.
14. Schwarz K et al. Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin. J Clin Invest 2001; 108: 1621-1629.
15. Huber TB et al. Interaction with podocin facilitates nephrin signaling. J Biol Chem 2001; 276: 41543-41546.
16. Huber TB et al. Molecular basis of the functional podocin-nephrin complex: mutations in the NPHS2 gene disrupt nephrin targeting to lipid raft microdomains. Hum Mol Genet 2003; 12: 3397-3405.
17. Huber TB et al. Podocin and MEC-2 bind cholesterol to regulate the activity of associated ion channels. Proc Natl Acad Sci USA 2006; 103: 17079-17086.
18. Huber TB et al. The slit diaphragm: a signaling platform to regulate podocyte function. Curr Opin Nephrol Hypertens 2005; 14: 211-216.
19. Hinkes B et al. Specific podocin mutations correlate with age of onset in steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2008; 19: 365-371.
20. Kim JM et al. CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science 2003; 300: 1298-1300.
21. Dustin ML et al. A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. Cell 1998; 94: 667-677.
22. Shih NY et al. Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science 1999; 286: 312-315.
23. Gigante M et al. CD2AP mutations are associated with sporadic nephrotic syndrome and focal segmental glomerulosclerosis (FSGS). Nephrol Dial Transplant 2009; 24: 1858-1864.
24. Huber TB et al. Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling. Mol Cell Biol 2003; 23: 4917-4928.
25. Kaplan JM et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 2000; 24: 251-256.
26. Brown EJ et al. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet 2010; 42: 72-76.
27. Michaud JL et al. FSGS-associated alpha-actinin-4 (K256E) impairs cytoskeletal dynamics in podocytes. Kidney Int 2006; 70: 1054-1061.
28. Boyer O et al. Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis. J Am Soc Nephrol. 2011; 22: 239-245.
29. Reiser J et al. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet 2005; 37: 739-744.
30. Winn MP et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005; 308: 1801-1804.
31. Greka A et al. Balancing calcium signals through TRPC5 and TRPC6 in podocytes. J Am Soc Nephrol 2011; 22: 1969-1980.
32. Moller CC et al. Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J Am Soc Nephrol 2007; 18: 29-36.
33. Huber TB et al. Bigenic mouse models of focal segmental glomerulosclerosis involving pairwise interaction of CD2AP, Fyn, and synaptopodin. J Clin Invest 2006; 116: 1337-1345.
34. Quaggin SE et al. Apolipoprotein l1 and the genetic basis for racial disparity in chronic kidney disease. J Am Soc Nephrol 2011; 22: 1955-1958.
35. Genovese G et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841-845.
36. Faul C et al. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol 2007; 17: 428-437.
37. Reiser J et al. Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. J Biol Chem 2004; 279: 34827-34832.
38. Zhu L et al. Activation of RhoA in podocytes induces focal segmental glomerulosclerosis. J Am Soc Nephrol 2011; 22: 1621-1630.
39. Attias O et al. Rac1 contributes to actin organization in glomerular podocytes. Nephron Exp Nephrol 2010; 114: e93-e106.
40. Asanuma K et al. Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat Cell Biol 2006; 8: 485-491.
41. Tcherkezian J et al. Current knowledge of the large RhoGAP family of proteins. Biol Cell 2007; 99: 67-86.
42. Akilesh S et al. Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis. J Clin Invest 2011; 121: 4127-4137.
43. Mele C et al. MYO1E mutations and childhood familial focal segmental glomerulosclerosis. N Engl J Med 2011; 365: 295-306.
44. Sever S et al. Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. J Clin Invest 2007; 117: 2095-2104.
45. Reiser J et al. Specialized roles for cysteine cathepsins in health and disease. J Clin Invest 2010; 120: 3421-3431.
46. Grunkemeyer JA et al. CD2-associated protein (CD2AP) expression in podocytes rescues lethality of CD2AP deficiency. J Biol Chem 2005; 280: 29677-29681.
47. Schiffer M et al. A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-beta-induced apoptosis. J Biol Chem 2004; 279: 37004-37012.
48. Woroniecki RP et al. Glomerular expression of transforming growth factor-beta (TGF-beta) isoforms in mice lacking CD2-associated protein. Pediatr Nephrol 2006; 21: 333-338.
49. Schiffer M et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001; 108: 807-816.
50. Asanuma K et al. Nuclear relocation of the nephrin and CD2APbinding protein dendrin promotes apoptosis of podocytes. Proc Natl Acad Sci USA 2007; 104: 10134-10139.
51. Yaddanapudi S et al. CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. J Clin Invest 2011; 121: 3965-3980.
52. Inoki K et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 2011; 121: 2181-2196.
53. Godel M et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 2011; 121: 2197-2209.
54. Huber TB et al. mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. Kidney Int 2011; 79: 502-511.
55. Wei C et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011; 17: 952-960.
56. Ponticelli C et al. Posttransplant recurrence of primary glomerulonephritis. Clin J Am Soc Nephrol 2010; 5: 2363-2372.
57. Wei C et al. Modification of kidney barrier function by the urokinase receptor. Nat Med 2008; 14: 55-63.
58. Smeets B et al. Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis. J Am Soc Nephrol 2011; 22: 1262-1274.